How Oral GLP-1s Work: Sublingual Absorption, SNAC Technology, and Why Format Matters
Every oral GLP-1 product is trying to solve the same underlying problem: semaglutide and tirzepatide are peptides, and peptides don't survive a trip through the digestive system by default. How each product tries to solve that problem is where they stop being interchangeable.
The Basic Problem: Your Stomach Is Built to Destroy Peptides
Semaglutide is a 31-amino-acid peptide, roughly 4,000 daltons. Your stomach is an acidic environment (pH 1.5–3.5) full of enzymes like pepsin whose entire job is to break protein and peptide bonds apart during digestion. Swallow semaglutide with no protection, and the vast majority of it gets broken down before it can reach the bloodstream at all. This is why, until oral formulations existed, every approved GLP-1 was an injection — injecting bypasses digestion entirely and gets close to 100% of the dose into circulation.
SNAC: The Technology Behind Rybelsus and the Wegovy Pill
Novo Nordisk's solution, first used in Rybelsus and later in the Wegovy pill, is a molecule called SNAC (sodium N-(8-[2-hydroxybenzoyl]amino)caprylate). It's not new technology invented for GLP-1s — it was originally developed for oral vitamin B12 formulations. SNAC does three specific things inside the stomach:
- Local pH buffering around the tablet, which slows down pepsin's ability to degrade the semaglutide before it can be absorbed.
- Monomerization — it keeps semaglutide molecules from clumping together, since individual molecules absorb more easily than aggregated clusters.
- Membrane fluidization of the stomach's epithelial lining, which allows semaglutide to pass directly through stomach cells (a transcellular route) rather than needing to squeeze between them.
Importantly, SNAC does not work by disrupting the tight junctions between cells or damaging the stomach lining — it's a targeted, reversible mechanism, not a blunt-force permeability hack. Even with all three effects working together, the FDA label puts oral semaglutide's bioavailability at only about 0.4% to 1%. That's why the oral tablets are dosed at 3–25mg while the injectable pen works at doses roughly 100 times smaller — the pill has to contain vastly more drug to get a therapeutic amount absorbed.
| Format | Absorption route | Validated in humans? |
|---|---|---|
| SNAC-enabled tablet (Rybelsus, Wegovy Pill) | Transcellular, in the stomach | Yes — FDA label, ~0.4–1% bioavailability |
| Small-molecule tablet (Foundayo) | Standard intestinal absorption, no enhancer needed | Yes — doesn't require permeation enhancement at all |
| Sublingual drops | Theorized mucosal absorption under the tongue | No published human bioavailability data |
| Dissolvable / ODT tablets | Theorized mucosal or swallowed absorption | No published human bioavailability data |
Foundayo: A Completely Different Approach
Orforglipron (Foundayo) doesn't use SNAC or any permeation enhancer at all, because it isn't a peptide. It's a small, non-peptide molecule engineered from the ground up to activate the GLP-1 receptor while being absorbed the way most conventional oral drugs are — through normal intestinal absorption. That's the entire reason it doesn't need the empty-stomach, wait-30-minutes dosing ritual that Rybelsus and the Wegovy pill require: there's no local stomach chemistry it depends on.
Sublingual Drops: A Different Theory, With a Much Bigger Evidence Gap
Compounded sublingual products work on an entirely different premise: instead of getting the peptide through the stomach, hold it under the tongue and let it absorb through the mucosal tissue there, bypassing the stomach altogether. This is a real absorption route for some drugs — sublingual nitroglycerin is a classic example — but it tends to work well for small, lipid-soluble molecules that can passively diffuse across mucosal membranes. Semaglutide, at roughly 4,000 daltons, is a large, water-soluble peptide, which is a poor match for passive sublingual absorption.
No SNAC-equivalent enhancer has been validated for sublingual use, and there is currently no published human clinical trial establishing a specific bioavailability figure for sublingual semaglutide or tirzepatide. That doesn't necessarily mean the products do nothing — but it does mean the "it bypasses the stomach so it should work" logic is a hypothesis, not an established mechanism with human data behind it, the way SNAC's mechanism is.
Why This Matters for Choosing a Product
Format isn't just a convenience question — it's the difference between a mechanism that's been measured in humans and one that hasn't. If evidence behind the exact mechanism matters to your decision, that alone might steer you toward the SNAC-based tablets or Foundayo over a sublingual drop, regardless of price. If you've already decided the compounded route is right for your budget or access needs, it's still worth understanding that you're relying on an unproven absorption theory rather than a validated one. For the full provider-by-provider breakdown by format, see our format comparison guide.